Rimegepant

Rimegepant (BMS-927711) is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM and an IC50 of 0.14 nM for hCGRP receptor. Rimegepant can be used for migraine research[1][2][3].

Product Specifications

CAS Number

[1289023-67-1]

Product Name Alternative

BMS-927711; BHV-3000

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

CGRP Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/BMS-927711.html

Purity

99.99

Solubility

DMSO : 10 mg/mL (ultrasonic; warming) |Ethanol : 4.4 mg/mL (ultrasonic)

Smiles

N[C@H]1[C@H](C2=C(F)C(F)=CC=C2)CC[C@@H](OC(N3CCC(N4C(C=CC=N5)=C5NC4=O)CC3)=O)C6=NC=CC=C61

Molecular Formula

C28H28F2N6O3

Molecular Weight

534.56

Precautions

H315, H319, H320

References & Citations

[1]Luo G, et al. Discovery of (5S,6S,9R) -5-amino-6- (2,3-difluorophenyl) -6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711) : an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012 Dec 13;55 (23) :10644-51.|[2]Vladimir Coric, et al. Dual treatment of migraine. WO2022251752. 2022-12-29.|[3]Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023 Mar;37 (3) :255-265. doi: 10.1007/s40263-023-00988-8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37 (7) :661.